Servier buys into MacroGenics' Phase I anticancer MAb
02 December 2011
Eleanor Malone
Please Login to read the full article.
02 December 2011
Eleanor Malone
eleanor.malone@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Oxford BioMedica break-even still just out of reach
- AVEO's unconvincing Phase II ficlatuzumab data point to need for further studies
- Cancer developer Merrimack dives into a tough IPO pool with a $172M filing
- Aveo licences preclinical RON-targeted antibodies to J&J, for $15 million up front
ANALYSIS
Other Informa Analysis
FEATURES
Other Informa Features
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
